U.S. flag An official website of the United States government
  1. Home
  2. Vaccines, Blood & Biologics
  3. Vaccines
  4. December 30, 2014 Approval Letter - Pneumovax 23
  1. Vaccines

December 30, 2014 Approval Letter - Pneumovax 23

Our STN:   BLS 101094/5933
Merck Sharp & Dohme Corp.
Attention:  Chitrananda P. Abeygunawardana
P.O. Box 1000, UG2D-68
North Wales, PA 19454-1099

Dear Dr. Abeygunawardana:

We have approved your request to supplement to your biologics license application for
Pneumococcal Vaccine, Polyvalent, PNEUMOVAX ® 23, to include a 2D barcode on the single dose pre-filled syringe label.

Please provide your final content of labeling in Structured Product Labeling (SPL) format and include the carton and container labels.  In addition, please submit three original paper copies for carton and container final printed labeling.  All final labeling should be submitted as Product Correspondence to this BLA at the time of use (prior to marketing) and include implementation information on FDA Form 356h.

In addition, please submit the final content of labeling (21 CFR 601.14) in SPL format via the FDA automated drug registration and listing system, (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm.  Information on submitting SPL files using eLIST may be found in the guidance for industry titled, “SPL Standard for Content of Labeling Technical Qs and as at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

You may submit two draft copies of the proposed introductory advertising and promotional labeling with an FDA Form 2253 to the Center for Biologics Evaluation and Research, Advertising and Promotional Labeling Branch, HFM-602, 1401 Rockville Pike, Rockville, MD 20852-1448. You must submit copies of your final advertisement and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f) (4)).

All promotional claims must be consistent with and not contrary to approved labeling.  You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims
(21 CFR 202.1(e) (6)).

We will include information contained in the above-referenced supplement in your biologics license application file.

 

Sincerely yours,

Wellington Sun, M.D.
Director
Division of Vaccines and
Related Products Applications
Office of Vaccines
Research and Review
Center for Biologics                                                   
Evaluation and Research

Attachment: Approved Final Draft Labeling